Futura Medical (AIM:FUM) told investors that a new Home User Test of its optimised Eroxon Intense presentation delivered better results across all key measures than both the original Intense formula and the standard Eroxon gel.
The AIM-listed consumer healthcare company, best known for its Eroxon erectile dysfunction gel, tested the updated presentation in 115 men aged 18 to 59, most with mild to moderate erectile dysfunction, using a study design matched to its previous test for direct comparison.
Participants reported satisfactory erection hardness in 82% of sexual encounters, against 71% for the original Intense presentation and 70% for standard Eroxon in the earlier study, while erections lasted long enough for intercourse in 87% of encounters, up from 85% and 84% respectively.
On the IIEF-EF clinical scale, participants recorded a 7.86-point improvement from baseline, more than the 4.82-point gain seen with the original Intense presentation, exceeding the threshold generally regarded as clinically meaningful.
The improvement was most pronounced among men with moderate erectile dysfunction, where 87% achieved a clinically meaningful gain, against 73% in the prior study.
Eroxon Intense is a faster-acting, higher-sensation variant of the original gel, cleared for launch across the European Economic Area and UK under Futura's existing CE and UKCA certifications following regulatory clearance reported at the end of July; commercial partner Cooper Consumer Health is set to bring it to market in its licensed territories.
"We are very encouraged by the results of this additional Home User Test," said Ken James, Futura's executive director and head of research and development, adding that "effective positioning and communication around the use of the product will be critical in improving customer satisfaction."
The company said work to finalise the product's market positioning is nearing completion ahead of the planned launch in the first half of 2027.